Lactobacillus acidophilus and application thereof in production of pyrroloquinoline quinone

Abstract

The invention provides lactobacillus acidophilus and application of the lactobacillus acidophilus in production of pyrroloquinoline quinone. The preservation number of the lactobacillus acidophilus is CCTCC (China Center for Type Culture Collection) NO: M 2025144. The 16SrDNA (deoxyribonucleic acid) sequence of the lactobacillus acidophilus TG002 is as shown in SEQ ID No: 1. The yield of pyrroloquinoline quinone produced by the lactobacillus acidophilus TG002 is high.

Description

Technical Field

[0001] The present invention relates to a Lactobacillus acidophilus strain and its application in producing pyrroloquinoline quinone, belonging to the field of microbial technology. Background Art

[0002] Pyrroloquinoline quinone (PQQ) is an aromatic tricyclic orthoquinone that can serve as the redox cofactor of many prokaryotic dehydrogenases (such as alcohol and sugar dehydrogenases) and is an essential nutrient for the human body. As a water-soluble vitamin-like substance discovered in the late 1970s, as a redox enzyme cofactor, it participates in the electron transfer of the respiratory chain and is the third coenzyme discovered after flavin nucleotide and nicotinamide nucleotide. In the fields of food and health products, PQQ plays a particularly prominent role as a new type of nutritional fortifier. It can not only significantly enhance the body's immunity, effectively scavenge free radicals in the body by promoting antioxidant reactions, reduce cell damage, but also actively participate in the energy metabolism process and optimize the energy utilization efficiency. In aspects such as neuroprotection, cardiovascular health maintenance, and diabetes treatment, PQQ has shown unique pharmacological effects and has attracted much attention in the medical field.

[0003] Fermented foods and beverages contain PQQ. Vegetables such as parsley and green peppers, fruits such as kiwifruit and papaya, teas such as green tea and oolong tea, and tofu all contain PQQ. In addition, PQQ exists in various tissues of the human body, especially in breast milk, and PQQ is an essential growth factor for development. It is not convenient to intake PQQ through other channels, and conventional PQQ production technologies are complex, including chemical synthesis methods and microbial fermentation methods. The chemical synthesis method has disadvantages such as a long reaction route and serious environmental pollution, while the microbial fermentation synthesis method has advantages such as a controllable production process, reusable strains, less environmental pollution, and high production safety. Microorganisms are important and irreplaceable for the human body. Probiotics that can produce high-yield PQQ can be used to supplement the PQQ required by the human body, play a role in scavenging free radicals and slowing down aging, and can also maintain the balance of the human intestinal microbiota.

[0004] Most strains achieve high-yield PQQ through a methanol carbon source medium, which adds many cumbersome purification steps during human intake. The Lactobacillus acidophilus obtained in this experiment can produce high-yield PQQ in the MRS-TG medium, reducing the influence of methanol as a fermentation substrate.

[0005] Lactobacillus acidophilus, as a probiotic with probiotic functions, has important value in maintaining and promoting human health, especially in regulating the balance of intestinal microecology, enhancing immunity, and preventing diseases. Lactobacillus acidophilus can secrete various antibacterial substances, such as acidophilin, acidobacillin, lactobacillin, etc., which have inhibitory effects on pathogenic bacteria in the intestine, such as Candida albicans, Escherichia coli, Helicobacter pylori, Salmonella, Shigella, and Staphylococcus, thereby reducing the number of harmful bacteria and preventing their overgrowth. By stimulating intestinal immune cells, Lactobacillus acidophilus can enhance the immune function of the body, improve resistance, and enable the body to better resist the invasion of external pathogens. Lactobacillus acidophilus can also decompose complex components such as carbohydrates, proteins, and fats in food, convert them into small molecules that the body can directly absorb, and improve the absorption and utilization efficiency of nutrients by the human body. For people with lactose intolerance, Lactobacillus acidophilus can help decompose lactose, relieve or eliminate discomfort symptoms such as diarrhea, abdominal distension, and flatulence caused by lactose intolerance, enabling them to better absorb the nutrients in dairy products.

[0006] However, there is no report in the prior art on Lactobacillus acidophilus that can produce pyrroloquinoline quinone. Summary of the Invention

[0007] The present invention provides a strain of Lactobacillus acidophilus and its application in the production of pyrroloquinoline quinone, which can effectively solve the above problems.

[0008] The present invention is realized as follows:

[0009] A strain of Lactobacillus acidophilus TG002, with the preservation number of CCTCC NO:M 2025144.

[0010] In some embodiments, the 16S rDNA sequence of the Lactobacillus acidophilus TG002 is as shown in SEQ ID No:1.

[0011] A probiotic product, comprising the Lactobacillus acidophilus TG002.

[0012] An antioxidant product, comprising the Lactobacillus acidophilus TG002.

[0013] An application of the Lactobacillus acidophilus TG002 in the preparation of pyrroloquinoline quinone.

[0014] In some embodiments, after inoculating the seed liquid of Lactobacillus acidophilus TG002 into a culture medium and culturing, the cell products are extracted.

[0015] In some embodiments, the culture medium contains ammonium sulfate and riboflavin.

[0016] In some embodiments, the culturing conditions are: 36 - 44°C, anaerobic culture.

[0017] Use of Lactobacillus acidophilus TG002 as described above in the preparation of antioxidant products.

[0018] The beneficial effects of the present invention are:

[0019] Lactobacillus acidophilus TG002 of the present invention has a high yield of pyrroloquinoline quinone and strong antioxidant ability.

[0020] Lactobacillus acidophilus TG002 of the present invention has good gastrointestinal fluid tolerance, and its survival rate in the body can be guaranteed.

[0021] Lactobacillus acidophilus TG002 of the present invention is of human origin, has high stability and safety, no toxic effects, and provides more choices for subsequent drug formulations. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the following will briefly introduce the drawings required for the embodiments. It should be understood that the following drawings only show some embodiments of the present invention, and therefore should not be regarded as limiting the scope. For those of ordinary skill in the art, other related drawings can also be obtained based on these drawings without creative efforts.

[0023] Figure 1 For PQQ standard - 6 - concentration PQQ standard curve (spectrometric method).

[0024] Figure 2 Schematic diagram of the plate morphology of Lactobacillus acidophilus TG002 strain.

[0025] Figure 3 Phylogenetic tree of Lactobacillus acidophilus TG002.

[0026] Figure 4 Growth curve of Lactobacillus acidophilus TG002.

[0027] Figure 5 Optimum temperature experiment of Lactobacillus acidophilus TG002.

[0028] Figure 6 Optimum pH experiment of Lactobacillus acidophilus TG002.

[0029] Figure 7 For PQQ standard - 5 - concentration PQQ standard curve (HPLC method).

[0030] Figure 8 PQQ liquid phase determination peak diagram. DETAILED DESCRIPTION OF THE EMBODIMENTS

[0031] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the following will clearly and completely describe the technical solutions in the embodiments of the present invention with reference to the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are some, but not all, of the embodiments of the present invention. All other embodiments obtained by those of ordinary skill in the art based on the embodiments of the present invention without creative efforts fall within the scope of protection of the present invention. Therefore, the following detailed description of the embodiments of the present invention provided in the accompanying drawings is not intended to limit the scope of the claimed invention, but merely represents selected embodiments of the present invention. All other embodiments obtained by those of ordinary skill in the art based on the embodiments of the present invention without creative efforts fall within the scope of protection of the present invention.

[0032] An embodiment of the present invention provides a strain of Lactobacillus acidophilus TG002, and its deposit number is CCTCC NO: M2025144.

[0033] In some embodiments, the 16S rDNA sequence of the Lactobacillus acidophilus TG002 is as shown in SEQ ID No: 1. This strain is derived from the feces of healthy people and has high safety. This strain has a high ability to produce pyrroloquinoline quinone (PQQ) and significant antioxidant enzyme activity.

[0034] An embodiment of the present invention provides a probiotic product, including the Lactobacillus acidophilus TG002.

[0035] An embodiment of the present invention provides an antioxidant product, including the Lactobacillus acidophilus TG002.

[0036] An embodiment of the present invention provides an application of the Lactobacillus acidophilus TG002 in the preparation of pyrroloquinoline quinone.

[0037] In some embodiments, after inoculating the seed solution of Lactobacillus acidophilus TG002 into a culture medium and culturing, the cell products are extracted.

[0038] In some embodiments, the culture medium contains ammonium sulfate and riboflavin. Ammonium sulfate and riboflavin are fermentation substrates for the strain to ferment PQQ, and appropriate addition can increase the proliferation ability of the PQQ-producing strain.

[0039] In some embodiments, the culture conditions are: 36 - 44 °C, anaerobic culture. Under these culture conditions, the strain has a strong ability to produce PQQ.

[0040] An application of the Lactobacillus acidophilus TG002 in the preparation of an antioxidant product.

[0041] Example 1 Screening and Identification of Lactobacillus acidophilus

[0042] Use methanol screening medium (g / L): methanol: 0.03, ammonium sulfate 1.0, disodium hydrogen phosphate 1.0, magnesium sulfate 1.0, potassium dihydrogen phosphate 1.4. For strain screening, the donor fecal samples were from the feces of healthy adults in Xiamen, Fujian and Xinjiang regions. The donor feces were diluted and spread on the methanol screening medium, and single colonies were picked for enlarged culture. Repeat the experiment, and inoculate the cultured strains onto the methanol screening medium to confirm the PQQ-producing ability of the strains.

[0043] Pick the strains that can grow on the methanol screening medium and inoculate them on the MRS plate for streak purification. The plate morphology is as Figure 2 shown. Pick a single colony and culture it in 5 mL of MRS liquid medium until the bacterial solution becomes turbid, and then store it at -80 °C.

[0044] Inoculate the seed solution of the test strains screened from the methanol screening medium into LB liquid medium, and then place it under constant temperature conditions at 37 °C for 48 h of fermentation culture to fully promote the growth and metabolism of the strains. After the culture is completed, quickly transfer the culture solution to a centrifuge tube, ultrasonically disrupt it at 200 W for 10 min, and centrifuge it at 5000 rpm for 5 min to effectively separate the bacteria from the supernatant, and collect the supernatant to complete the preparation of cell-free extracts. Use an enzyme-labeling instrument to measure the absorbance of the collected supernatant at a wavelength of 326 nm. Dilute the PQQ standard product (4, 5, 10, 15, 20, 25 μg / mL) to construct a PQQ standard curve. The PQQ standard curve is as Figure 1 shown. As Figure 1 shown, the standard curve equation of PQQ is: Y = 0.01636X + 0.2254, R 2 = 0.9999 ( Figure 1 ), which meets the experimental design.

[0045] Perform spectral measurement on 30 probiotic strains screened from human fecal samples, and screen out one strain with the highest PQQ production concentration of 1.22 μg / mL. The strain was cultured in MRS liquid medium, and the genomic DNA of the strain was extracted using a bacterial genomic DNA rapid extraction kit. Using the extracted genomic DNA as a template, PCR amplification was carried out, and the amplified PCR products were sent for sequencing. The sequences obtained by sequencing were compared by Blast on the NCBI website. The results showed that the strain was a Lactobacillus acidophilus, and its 16S rDNA sequence was as follows:

[0046] ACGGCTCCTTCCCGAAGGTTAGGCCACCGGCTTTGGGCATTGCAGACTCCCATGGTGTGACGGGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCGGCGTGCTGATCCGCGATTACTAGCGATTCCAGCTTCGTGCAGTCGAGTTGCAGACTGCAGTCCGAACTGAGAACAGCTTTAAGAGATTCGCTTGCCTTCGCAGGCTTGCTCCTCGTTGTACTGTCCATTGTAGCACGTGTGTAGCCCAGGTCATAAGGGGCATGATGACTTGACGTCATCCCCACCTTCCTCCGGTTTGTCACCGGCAGTCTCATTAGAGTGCCCAACTTAATGCTGGCAACTAATGACAAGGGTTGCGCTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAGCCATGCACCACCTGTCTTAGTGTCCCCGAAGGGAACTCCGTATCTCTACGGATTGCACTAGATGTCAAGACCTGGTAAGGTTCTTCGCGTTGCTTCGAATTAAACCACATGCTCCACCGCTTGTGCGGGCCCCCGTCAATTCCTTTGAGTTTCAACCTTGCGGTCGTACTCCCCAGGCGGAGTGCTTAATGCGTTAGCTGCAGCACTGAGAGGCGGAAACCTCCCAACACTTAGCACTCATCGTTTACGGCATGGACTACCAGGGTATCTAATCCTGTTCGCTACCCATGCTTTCGAGCCTCAGCGTCAGTTGCAGACCAGAGAGCCGCCTTCGCCACTGGTGTTCTTCCATATATCTACGCATTCCACCGCTACACATGGAGTTCCACTCTCCTCTTCTGCACTCAAGAAAAACAGTTTCCGATGCAGTTCCTCGGTTAAGCCGAGGGCTTTCACATCAGACTTATTCTTCCGCCTGCGCTCGCTTTACGCCCAATAAATCCGGACAACGCTTGCCACCTACGTATTACCGCGGCTGCTGGCACGTAGTTAGCCGTGACTTTCTGGTTGATTACCGTCAAATAAAGGCCAGTTACTACCTCTATCCTTCTTCACCAACAACAGAGCTTTACGATCCGAAAACCTTCTTCACTCACGCGGCGTTGCTCCATCAGACTTTCGTCCATTGTGGAAGATTCCCTACTGCTGCCTCCCGTAGGAGTTTGGGCCGTGTCTCAGTCCCAATGTGGCCGATCAGTCTCTCAACTCGGCTATGCATCATTGCCTTGGTAGGCCGTTACCCTACCAACTAGCTAATGCACCGCGGGGCCATCCCATAGCGACAGCTTACGCCGCCTTTTATAAGCTGATCATGCGATCTGCTTTCTTATCCGGTATTAGCACCTGTTTCCAAGTGGTATCCCAGACTATGGGGCAGGTTCCCCACGTGTTACTCACCCATCCGCCGCTCGCGTTCCCAACGTCATCACCGAAGTGAATCTGTTGGTTCAGCTCGCTCGAC(SEQ ID No:1).

[0047] When this strain was compared with the BlAST on the NCBI website, it was found that the similarity between this strain and the known Lactobacillus acidophilus VPI 6032 (sequence ID: NR_117062.1) was more than 99%. In order to further understand the position of this strain in the phylogenetic relationship, a phylogenetic tree was constructed by the Neighbor-joining (NJ) method combined with the existing Lactobacillus acidophilus sequences. The phylogenetic relationship is as Figure 3 shown in the phylogenetic tree, indicating that this strain belongs to Lactobacillus acidophilus and is named Lactobacillus acidophilus TG002. It was deposited in the China Center for Type Culture Collection on January 15, 2025, with the deposit number: CCTCC NO: M 2025144, and the deposit address is Wuhan, China.

[0048] Example 2 Physicochemical properties of Lactobacillus acidophilus TG002

[0049] 1. Activation of Lactobacillus acidophilus TG002 seed liquid

[0050] The strain was taken out of the -80 °C refrigerator and streaked and activated on an MRS agar plate using a disposable inoculation loop, and cultured in an anaerobic incubator at 37 °C until single colonies grew. Seed liquid: A single colony on the MRS agar plate was picked up with a disposable inoculation loop and inoculated into 5 mL of MRS medium, shaken well, and placed in a shaker at 37 °C and 200 r / min for 24 h.

[0051] 2. Determination of growth curve

[0052] The seed liquid OD 600 was diluted in the range of 0.8 - 1.0, and inoculated into 5 mL of MRS liquid medium at an inoculation amount of 1% (50 μL) (12 groups, n = 3). After inoculation, it was placed in a shaker at 37 °C and 200 r / min for culture. One group was taken out every 2 h for OD 600 determination until the strain completed logarithmic growth and reached the plateau phase.

[0053] The logarithmic growth phase of Lactobacillus acidophilus TG002 growth curve is 8 - 12 h, and it enters the plateau phase at 16 h ( Figure 4 ).

[0054] 3. Determination of the optimum temperature

[0055] The seed liquid OD 600 was diluted in the range of 0.8 - 1.0, and inoculated into 5 mL of MRS liquid medium at an inoculation amount of 1% (50 μL) (n = 3). After inoculation, it was placed in a shaker at 27, 32, 37, 42, 47 °C and 200 r / min for culture. And at appropriate time points (the bacterial liquid in some groups became turbid), it was taken out for OD600 。

[0056] As Figure 5 shown, the optimum growth temperature of Lactobacillus acidophilus TG002 is 42 °C.

[0057] 4. Determination of Optimum Growth pH

[0058] Dilute the seed liquid OD 600 in the range of 0.8 - 1.0, and inoculate it into 5 mL of MRS liquid medium with different pH gradients (pH = 4, 5, 6, 7, 8) at an inoculation amount of 1% (50 μL) (n = 3). Place it in a shaker and culture anaerobically at 37 °C and 200 r / min. Take samples at appropriate time points (turbidity appears in the bacterial liquid of some groups) to measure OD 600 。

[0059] As Figure 6 shown, the optimum growth pH of Lactobacillus acidophilus TG002 is pH = 7.

[0060] Example 3 Determination of the Ability of Lactobacillus acidophilus TG002 to Produce PQQ (HPLC Method)

[0061] Due to the limitations of spectrometric determination of concentration, high-performance liquid chromatography was used to accurately quantify the PQQ production of Lactobacillus acidophilus TG002.

[0062] Use MRS-TG medium (g / L): casein peptone 10.0, beef extract powder 10.0, yeast extract powder 4.0, ammonium citrate 2.0, sodium acetate 5.0, magnesium sulfate 0.2, ammonium sulfate 2.0, manganese sulfate 0.05, dipotassium hydrogen phosphate 2.0, glucose 20.0, Tween-80 1.08, riboflavin 1.0. Pipette 100 μL of the seed liquid of Lactobacillus acidophilus TG002 strain and inoculate it into 10 mL of MRS-TG medium and culture at 37 °C 、 After anaerobic culture for 48 h, transfer the culture solution to a centrifuge tube, ultrasonically disrupt it at 200 W for 10 min, and centrifuge it at 5000 rpm for 5 min to complete the preparation of cell-free extract.

[0063] Prepare a 1 mg / mL PQQ standard solution, and dilute the standard solution concentration to 1000 μg / mL, 800 μg / mL, 500 μg / mL, 200 μg / mL, 100 μg / mL.

[0064] Mobile phase preparation: water + 1‰ TFA (trifluoroacetic acid): acetonitrile + 1‰ TFA = 85:15 (V:V)

[0065] Detection conditions: Use a C18 chromatographic column (Waters), detection wavelength is 330 nm, column temperature is 40 °C, and flow rate is 0.5 mL / min.

[0066] The concentration gradients of the standard curve are 100 μg / mL, 200 μg / mL, 500 μg / mL, 800 μg / mL, and 1000 μg / mL in sequence. The retention time is 3 min. Make a standard curve as Figure 7 shown. Y = 56.5X - 1690, R 2 = 0.9996, meeting the linear relationship of the standard curve.

[0067] Filter the cell-free extract of Lactobacillus acidophilus TG002 through a 0.22 μm organic filter membrane and set aside. The detection method is the same as that for the standard product. The liquid chromatography determination peak diagram is as Figure 8 shown. It can be seen from Figure 8 that the peak area of the cell-free extract of Lactobacillus acidophilus TG002 is 4354, and the PQQ production is 106.97 μg / mL.

[0068] Example 4 Drug sensitivity experiment of Lactobacillus acidophilus TG002

[0069] Dilute the seed liquid OD 600 to the range of 0.8 - 1.0, pipette 50 μL onto the MRS solid medium, and spread evenly. After the bacterial liquid dries, use forceps to pick up the drug sensitivity discs (drug concentration is 20 μg) and distribute them regularly on the MRS medium (n = 3). Gently press the drug sensitivity discs with forceps to prevent them from falling off. Observe and record the size of the inhibition zone after anaerobic culture for 24 h. The experimental results are shown in Table 1.

[0070] Table 1 Drug sensitivity test results of Lactobacillus acidophilus TG002

[0071]

[0072]

[0073] It can be seen from Table 1 that Lactobacillus acidophilus TG002 is sensitive (S) to 8 drug sensitivity discs, intermediate (I) to 1, and resistant (R) to 7.

[0074] Example 5 Determination of antioxidant function of Lactobacillus acidophilus TG002

[0075] 1. Determination of the ability of Lactobacillus acidophilus TG002 to scavenge DPPH free radicals

[0076] Preparation of DPPH sample solution: Accurately weigh 20.0 mg of DPPH powder, place it in a 250 mL volumetric flask, dissolve it with absolute ethanol and make up to the mark, mix well to obtain a 0.2 mmol / L DPPH solution, and store it at 4°C (for use within 3.5 h).

[0077] Take 1 mL of the strain supernatant in Example 3, add 1 mL of DPPH with a concentration of 0.2 mmol / L, mix well, let it stand at room temperature for 30 min, then use absolute ethanol as a blank control and measure the absorbance change at 517 nm.

[0078] Measure the absorbance of the bacterial liquid supernatant + DPPH solution as A1 at a wavelength of 517 nm; use a mixture of 1.0 mL of DPPH solution and 1.0 mL of absolute ethanol as a negative control to measure the absorbance A2; use a mixture of 1.0 mL of absolute ethanol solution and 1.0 mL of bacterial liquid supernatant as a blank control and measure its absorbance A0. Calculate the scavenging rate according to the following formula.

[0079]

[0080] 2. Determination of superoxide dismutase (SOD) activity of Lactobacillus acidophilus TG002

[0081] Use a kit (Elabscience) to determine the SOD activity of the supernatant of Lactobacillus acidophilus TG002 bacterial liquid in Example 3.

[0082] The test results are shown in Table 2. As can be seen from Table 2, the scavenging rate of the supernatant of Lactobacillus acidophilus TG002 bacterial liquid against DPPH free radicals is 74.52%, and the SOD activity is 396.41 U / mL, proving that this strain of bacteria has good antioxidant ability.

[0083] Table 2 Antioxidant ability of the supernatant of Lactobacillus acidophilus TG002 bacterial liquid

[0084]

[0085] Determination in simulated gastrointestinal fluid in Example 6

[0086] Preparation of simulated gastric juice: Accurately measure 16.4 mL of dilute hydrochloric acid, add 800 mL of water and 10 g of pepsin and mix completely, add water to make up to 1000 mL and mix completely. Adjust the pH = 2.5 with 1 mol / L HCl, filter and sterilize with a 0.22 μm microporous membrane after complete dissolution, and set aside.

[0087] Preparation of simulated intestinal fluid: Accurately weigh 6.8 g of potassium dihydrogen phosphate and add 500 mL of water. Adjust the pH to 6.8 with 0.4% sodium hydroxide solution; separately take 10 g of trypsin and add an appropriate amount of water to dissolve it. Mix the two solutions and then make up the volume to 1000 mL with water. Adjust the pH to 8.0 with 0.1 mol / L NaOH, then fully dissolve and filter and sterilize with a 0.22 μm microporous membrane for standby.

[0088] After preparation, inoculate the bacterial solution into the gastrointestinal fluid medium at an inoculation amount of 1%. After inoculation, place it in a shaker at 37°C and 200 rpm and culture for 2.5 h.

[0089] Dilute each group to 10 -2 、10 -3 、10 -4 gradients, take 50 μL and spread it on a plate by dilution coating. Repeat each gradient three times. Place it in a biochemical incubator at 37°C and let it stand overnight until single colonies are formed. Count the colonies the next day. It is appropriate to count 10 - 300 single colonies on each plate.

[0090] After testing, in the gastrointestinal fluid resistance experiment, after 2.5 h, the gastric juice survival rate of Lactobacillus acidophilus TG002 was 29.98%, and the intestinal fluid survival rate was 32.91%.

[0091] The above is only the preferred embodiment of the present invention and is not used to limit the present invention. For those skilled in the art, the present invention can have various changes and modifications. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. An acidophilus lactobacillus TG002, characterized in that, Its preservation number is CCTCC NO: M2025144.

2. The Lactobacillus acidophilus TG002 according to claim 1, characterized in that, Its 16S rDNA sequence is shown as SEQ ID No:

1.

3. A probiotic product, characterized in that, It includes Lactobacillus acidophilus TG002 described in claim 1 or 2.

4. An antioxidant product, characterized in that, It includes Lactobacillus acidophilus TG002 described in claim 1 or 2.

5. Use of Lactobacillus acidophilus TG002 described in claim 1 or 2 for preparing pyrroloquinoline quinone.

6. The application according to claim 5, characterized in that, After inoculating the seed liquid of Lactobacillus acidophilus TG002 into a culture medium and culturing, the cell products are extracted.

7. The application according to claim 6, wherein The culture medium contains ammonium sulfate and riboflavin.

8. The application according to claim 6, wherein The conditions for the culture are: 36 - 44 °C, anaerobic culture.

9. Use of Lactobacillus acidophilus TG002 described in claim 1 or 2 for preparing antioxidant products.

Images